ONWARD Medical Begins EIGER Study With First ARC-IM Implant
Eindhoven, Netherlands, September 3, 2026 ONWARD Medical announced the first implant in the new EIGER clinical feasibility study, evaluating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Eindhoven, Netherlands, September 3, 2026 ONWARD Medical announced the first implant in the new EIGER clinical feasibility study, evaluating...
SOLANA BEACH, Calif., July 1, 2026 Artelo Biosciences, Inc. announced positive preclinical data demonstrating that its investigational drug candidate...
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
Eindhoven, Netherlands — Nov. 24, 2025 — ONWARD Medical N.V. announced a series of major scientific, regulatory, and commercial...
